^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLN-049

    i
    Other names: CLN-049
    Associations

    News

    Trials
    Company:
    Cullinan Therap, German Cancer Research Center, University of Tuebingen
    Drug class:
    FLT3 inhibitor, CD3 agonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) (EHA 2023)
    Eligible pts include adults with AML R/R to standard induction chemotherapy or venetoclax-based regimens and MDS R/R to hypomethylating agents (HMA)-based treatment...The first pt (baseline 47% BM blasts and receiving hydroxyurea to control leukocytosis) experienced Grade 2 CRS 5.5 hours after infusion that resolved within 24 hours with supportive care... Safety and PK data from the SAD portion supported initiation of the MAD study. Measurable cytokine induction consistent with biological activity was observed at the initial IV dose level tested. Enrollment to the Part C SC dose escalation is ongoing, and updated data will be presented.
    Clinical • P1 data
    |
    FLT3 (Fms-related tyrosine kinase 3) • IL6 (Interleukin 6) • IL10 (Interleukin 10)
    |
    FLT3 expression
    |
    Venclexta (venetoclax) • hydroxyurea • CLN-049
    over2years
    A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. (PubMed, J Immunother Cancer)
    CLN-049 has a favorable efficacy and safety profile in preclinical models, warranting evaluation of its antileukemic activity in the clinic.
    Journal • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • CD33 (CD33 Molecule) • CD4 (CD4 Molecule)
    |
    FLT3 mutation • FLT3 expression
    |
    CLN-049
    almost3years
    CLN-049 is a bispecific T cell engaging IgG-like antibody targeting FLT3 on AML cells (AACR 2022)
    In summary, CLN-049 is a promising FLT3-targeted T cell engaging antibody construct expected to have robust anti-tumor activity in the clinic against AML. CLN-049 is currently in a phase 1 clinical trial for the treatment of patients with relapsed/refractory AML.
    IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    FLT3 mutation • FLT3 expression
    |
    CLN-049
    3years
    CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=9, Recruiting, Cullinan Oncology, LLC
    Clinical • New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CLN-049